Publication

Article

Oncology Nursing News

December 2010
Volume4
Issue 6

Bone Loss Drugs Increase Stroke Risk in Patients With Cancer

Author(s):

Onclive Team

Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk

Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.

Articles in this issue
Net Guides: Melanoma
Net Guides: Melanoma
Net Guides: Bone Metastases
Net Guides: Bone Metastases
Yoga for Cancer Care
FDA Updates: March 7, 2011
The Future of Nursing
Net Guides: Liver Cancer
Net Guides: Carcinoma of Unknown Primary Orgin
Integrative Medicine and Cancer Treatment
Reimbursement for Nurse Navigation: It Can Be Done
Tools to Help Patients Navigate Their Treatment Path
John Theurer Cancer Center Opens New Comprehensive Facility
John Theurer Cancer Center Opens New Comprehensive Facility
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Oncology Community Facing Severe Drug Shortages
Oncology Community Facing Severe Drug Shortages
Net Guides: Oral Cancer
Net Guides: Oral Cancer
Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Susana M. Campos, MD, MPH
November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Whitney Goldsberry, MD
November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester
November 20th 2024

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer